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Abstract
The aim of this study was to compare different cell sources and culture conditions to obtain en-
dothelial progenitor cells (EPCs) with predictable antigen pattern, proliferation potential and in
vitro vasculogenesis. Pig mononuclear cells were isolated from blood (PBMCs) and bone marrow
(BMMCs). Mesenchymal stem cells (MSCs) were also derived from pig bone marrow. Cells were
cultured on fibronectin in the presence of a high concentration of VEGF and low IGF-1 and FGF-
2 levels, or on gelatin with a lower amount of VEGF and higher IGF-1 and FGF-2 concentrations.
Endothelial commitment was relieved in almost all PBMCs and BMMCs irrespective of the proto-
col used, whilst MSCs did not express a reliable pattern of EPC markers under these conditions.
BMMCs were more prone to expand on gelatin and showed a better viability than PBMCs. More-
over, about 90% of the BMMCs pre-cultured on gelatin could adhere to a hyaluronan-based scaf-
fold and proliferate on it up to 3 days. Pre-treatment of BMMCs on fibronectin generated well-
shaped tubular structures on Matrigel, whilst BMMCs exposed to the gelatin culture condition
were less prone to form vessel-like structures. MSCs formed rough tubule-like structures, irrespec-
tive of the differentiating condition used. In a relative short time, pig BMMCs could be expanded
on gelatin better than PBMCs, in the presence of a low amount of VEGF. BMMCs could better
specialize for capillary formation in the presence of fibronectin and an elevated concentration of
VEGF, whilst pig MSCs anyway showed a limited capability to differentiate into the endothelial
cell lineage.
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1. Introduction
Endothelial progenitor cells (EPCs) promote vasculogenesis and/
or ameliorate the process of angiogenesis, thereby improving both
regeneration and function of ischemic organs such as the infarcted
heart (1,2). EPCs can be easily isolated from peripheral blood or
bone marrow (3,4), expanded ex vivo, and then transplanted in
the damaged tissues. Superficial antigens including CD34,
CD133, and VEGFR-2 are often utilized to recognize EPCs dur-
ing their immature stage, whilst other markers such as VE-cad-
herin and CD31 characterize the lineage progression towards an
increased differentiation into endothelial cells (5,6).
In order to obtain EPCs, three fundamental strategies are usually
followed: (1) identifying EPCs by markers which are already present
in the putative immature endothelial stem cells (haemangioblast) (7),
(2) selectingEPCsby their ability to formendothelial-cell like clusters
(8), and (3) exploiting the plasticity of mononuclear cells (MNCs)
(9,10), the latter two conditions demanding the presence of specific
differentiating growth factors. The first strategy represents the only
way to immediately isolate EPCs after sample collection. However,
the isolation output is low and it takes a long time to reach a critical
cell number useful for clinic applications. In contrast, a greater num-
ber of EPCs can be more rapidly obtained from MNCs which can
generate two different subpopulations, the early and the late EPCs
(11,12). The former are usually described as MNCs which are forced
to express endothelial markers within a few days; their number is el-
evated after isolation but these cells cannot be further expanded and
they incorporate poorly into new vessels. Despite these apparent neg-
ative features, early EPCs efficiently promote in vivo neoangiogenesis
especially by producing specific growth factors and chemokines. On
the other hand, the number of late EPCs is extremely low after isola-
tion and they begin to proliferate only 2–3 weeks after seeding,
showing by that time an elevated proliferation potential and a satisfy-
ing ability for generating new vessels in vivo.
Although many characteristics regarding EPC isolation and
culture have been already described, some aspects still need to
be better defined: (1) the biological source of EPCs, since bone
marrow contains a number of immature progenitors which is
500-fold higher compared to peripheral blood (13); (2) the
choice between MNCs and mesenchymal stem cells (MSCs), be-
cause the latter have been described to induce neovascularization
by releasing angiogenic factors (14) and differentiating into endo-
thelial cells (15); and (3) the culture medium to be selected, due
to the complexity of the compounds which are dissolved therein
and their variable ability to stimulate differentiation and/or prolif-
eration of cells (16).
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The aim of this paper was to investigate and compare different
cell sources and culture conditions in order to obtain EPCs with
predictable antigen pattern and proliferation features, principally
addressed to therapeutic neovascularization. With a regard to suc-
cessive in vivo applications, for our study we chose the swine mod-
el which is increasingly used to investigate cardiovascular
pathologies due to its anatomical analogies with humans (17).
2. Material
and Methods
2.1. Cell Isolation
and Treatment
Animals received adequate care in accordance with the “Principle of
laboratory animal care” (NIH publicationN0. 86-23, revised 1985)
and with the specific Italian law (DL-116, 27 January 1992) which
complies with the guide for the care and use of laboratory animals.
2.1.1. Peripheral
Blood-Derived
Mononuclear Cells (PBMCs)
Two-month-old female pigs weighing 30–35 kg were sedated with a
zolazepam–tiletamine mixture; total anaesthesia was induced with
propofol and then maintained with isoflurane, fentanyl, and atracu-
rium besylate. Pigs were placed in a supine position and the right in-
ternal jugular vein was surgically isolated. About 40ml of bloodwere
then collected and introduced into a bag containing a citrate phos-
phate dextrose adenine (CPDA) solution in a 9 to 1 blood to preserv-
er ratio. PBMCs were isolated from venous blood by density
centrifugation on Ficoll gradient (Ficoll-Paque® plus; GE Health-
care, Uppsala, Sweden). PBMCs were then plated on culture dishes
coatedwith 5μg/ml human fibronectin or 1.5%gelatin. ThePBMCs
plated on fibronectin-coated dishes were maintained inMedium 119
(M119), plus penicillin and streptomycin, and supplementedwith es-
sential amino acids, 10% fetal calf serum (FCS), 50 ng/ml vascular
endothelial growth factor (VEGF), 1 ng/ml human fibroblast
growth factor-2 (FGF-2), and 2 ng/ml human insulin-like growth
factor-1 (IGF-1). All growth factors were from Peprotech, Rocky
Hill, NJ, USA. This experimental condition will be referred to here-
after as fibronectin culture condition, and the overall components
and substrates as fibronectin medium.
The PBMCs which were plated on gelatin-coated dishes were
maintained in endothelial cell basal medium supplemented with
EGM-2 (PromoCell, Heidelberg, Germany) containing: hydrocorti-
sone (200 ng/ml culture medium solution), 2% FCS, 0.5 ng/ml
VEGF, 10 ng/ml human FGF-2, 5 ng/ml human epidermal growth
factor (EGF), 20 ng/ml human IGF-1, and 1 μg/ml ascorbic acid.
The supplemented endothelial cell growth medium was integrated
with essential amino acids plus penicillin and streptomycin. This
enriched EGM-2 solution should promote cell proliferation better
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than cell differentiation with respect to the fibronectin medium, due
to the higher concentrations of FGF-2 and IGF-1 together with
EGF. This experimental condition will be referred to hereafter as gel-
atin culture condition, and the overall components and substrates as
gelatin medium.
2.1.2. Bone Marrow-Derived
Mononuclear Cells (BMMCs)
Pigs were placed on their right side and 50ml of bonemarrowwere
aspirated from the ileal crest and mixed at a 1:1 volume ratio with
M199 containing 5% sodium heparin. The sample was filtered onto
a 100-μmnylon cell strainer (BDFalcon, Franklin Lakes, NJ, USA)
and the mononuclear cell fraction (BMMCs) was isolated by den-
sity centrifugation on Ficoll gradient. BMMCs were exposed either
to the fibronectin or gelatin culture condition. Some experiments
were carried out by growing BMMCs under an intermediate cul-
ture condition consisting of fibronectin-coated dishes with the
EGM-2 supplemented solution (18,19).
2.1.3. Mesenchymal Stem
Cells (MSCs)
BMMCs were enriched in MSCs by growing them on plastic for
about 2 weeks. Pig bone marrow was aspirated according to the
above-mentioned procedure described for BMMC isolation. Cells
were filtered through a 100-µm nylon filter (BD Falcon) and plat-
ed into a 75-cm2 flask. Cells were then grown in complete αMEM
containing 10% fetal bovine serum (FBS), 2 mM L-glutamine,
100 U/ml penicillin, and 100µg/ml streptomycin at 37°C and
5% CO2 for 3 days. The medium was then replaced with fresh me-
dium and the adherent cells were grown for further 10–12 days
(MSCs), reaching about 90% confluence.
MSCs were cultured under both fibronectin and gelatin cul-
ture conditions for 1 week and then investigated for changes in
cell antigens and angiogenic functions. More detailed morpholog-
ic and immunophenotypic properties of bone-derived MSCs have
been described in our previous work (20,21).
2.2. Cytochemical
Characterization
Direct fluorescent staining was used to detect the binding of fluores-
cein isothiocyanate (FITC)-conjugated BS-I, a lectin obtained from
Bandeiraea simplicifolia (Sigma, St. Louis, Missouri, USA) (22) and
cell uptake of 1,1-dioctadecyl-3,3,3,3-tetramethilindocarbocyanine
(Dil)-labelled acetylated low density lipoprotein (acLDL;Molecular
Probes, Eugene, Oregon, USA). Cells were incubated with 10 μg/
ml acLDL for 4 h andwith 10μg/ml BS-I for 2 h at 37°C and finally
fixed with 3% paraformaldehyde in PBS for 15 min.
Regarding the immunofluorescence analysis, cells were grown
on glass coverslips under the differentiating conditions, fixed with
3%paraformaldehyde, and rinsed twicewith PBS.After blockingwith
4% BSA and 0.2% Tween 20 in PBS for 1 h at room temperature, the
cells were incubated with primary mouse monoclonal antibodies
against the following antigens: human VEGFR-2 1:20 (MAB3571;
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R&D Systems, Minneapolis, MN, USA; its cross-reactivity with pig
VEGFR-2 was verified in the present study); pig CD31 1:10
(MCA1746; AbD Serotec, Düsseldorf, Germany); pig macrophages
1:100 (MCA2317; AbD Serotec); human CD90 1:100 (550402;
BD Bioscience, Pharmingen, San Diego, CA, USA; cross-reactive
with pig CD90). All primary antibodies were diluted in the blocking
reagent. FITC-conjugated anti-mouse antibodies (Sigma) were used
as secondary antibodies (diluted in blocking buffer 1:2000). After im-
munofluorescence staining, cells were mounted with the bleaching
reagent (ProLongGold antifade reagent;Molecular Probes) on stan-
dard glass slide and observed by an inverted fluorescence microscope
(Olympus IX50).
Human umbilical vein endothelial cells (HUVECs; Lonza,War-
kerville,MD,USA) were chosen as positive control cells either for di-
rect fluorescence staining (Dil-acLDL, FITC-UEA-1) or
immunofluorescence analysis. More than 85% of HUVECs was pos-
itively stained by the above-mentioned endothelial markers (data not
shown). H9c2 rat cardiomyoblasts (ECACC) were used as negative
control cells. They were substantially not stained by the endothelial
markers, since at most 2.5% of them showed target- specific fluores-
cence (data not shown).
The percentage of cells staining positive to each fluorescent
markers was calculated using ten randomly selected high-power
fields for three separate experiments.
2.3. Cell Seeding
and Cell Adhesion on a
Hyaluronan-Based
Scaffold
The BMMCs were grown until confluence on coated dishes un-
der fibronectin-, gelatin-, or intermediate culture conditions, then
detached by incubation with 1% EDTA solution in PBS for
10 min at 37°C and counted in duplicate using a Burker hemocy-
tometer. Some aliquots of post-confluent BMMCs were re-seed-
ed on the coated dish under the same condition for 1 week to
obtain first passage cells. BMMCs were suspended in M199 and
slowly dispensed at the density of 1×104 cells/mm3 onto three-
dimensional pieces of HYAFF®11 (Fidia Advanced Biopolymers,
Abano Terme, Italy), a non-woven hyaluronan-based scaffold
(surface: 2–10 mm2; height: 1 mm), which were lodged in a
24-well cell culture plate (23). Cells were allowed to attach to
the scaffold for 3 h at 37°C before adding the complete culture
medium (M199 with growth factors or EGM-2).
The trypan blue exclusion staining method was used to quan-
tify cell adhesion into the biopolymer after 24 h from seeding.
The number of cells which adhered to the fibers was calculated
by subtracting the number of cells attached on the well bottom
and those still in suspension from the total amount of seeded cells:
HYAFF‐adherent cells ¼ total seeded cells
 well attached and suspended cells
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2.4. Cell Proliferation
and Viability
Cell expansion was measured by the trypan blue exclusion
staining method which allows the quantification of living cells
by counting them in a Bürker’s counting chamber. Cell via-
bility was assessed by using the Alamar Blue dye (BioSource,
Camarillo, CA), a nontoxic aqueous compound formulated to
quantify viability and proliferation of living cells. This method
consists in the indicator reduction into a fluorescent form in
response to changes in the mitochondrial redox activity. In
brief, adherent cells or cells seeded on the scaffold were incu-
bated after medium removal at 37°C for 4 h with 1 ml of
Alamar Blue solution (10% v/v in complete culture medium)
according to the manufacter’s instructions. Alamar Blue re-
duction was quantified in triplicate from each sample (Ex
540 nm/Em 590 nm) using a Wallac VICTOR2 multiwell
reader (Perkin Elmer, Milan, Italy).
2.5. In Vitro
Vasculogenesis
The assay was performed on Matrigel (BD Biosciences, Bedford,
MA, USA) according to manufacturer’s instructions. Briefly, ECma-
trix™ solution was placed in a 96-well tissue culture plate at 37°C for
1 h to allow the matrix solution to solidify. BMMCs or MSCs were
treated with the above-mentioned endothelial differentiating media
and successively detached with 1 mM EDTA/PBS at 37°C for
20 min, harvested by centrifugation, and re-plated alone (2.0×104
cells/well) or together with HUVECs (2.0×104 cells/well) on the
solidified matrix solution. Cells seeded on Matrigel were incubated
in M199 at 37°C for 24 h and tubule-like formation was then
inspected under an inverted light microscope (Olympus IX50).
2.6. Statistical
Analysis
Values are expressed as the mean ± standard error of the mean.
The statistical analysis was performed by unpaired Student’s t test.
PG0.05 was considered significant.
3. Results
3.1. Experiments
with PBMMCs
and BMMCs
3.1.1. PBMMC
and BMMC Commitment
to the Endothelial Cell
Lineage
Almost all PBMCs were positive to both acLDL uptake and BS-I
binding after just 1 week of fibronectin culture condition (Table 1).
These two markers were readily detectable in more than 90% of
cells even only 3 weeks after cell seeding. VEGFR-2 was expressed
by about 75% of PBMCs after 1 week and by 95% of cells after 2
and 3 weeks. In contrast, the mature endothelial cell marker
CD31 and the macrophage antigen were present only at a low per-
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centage in PBMCs throughout the experiment. Moreover, CD90
was not expressed suggesting that adherent PBMCs were not ori-
ented toward the mesenchymal lineage.
Nearly all PBMCs exposed to the gelatin medium for 1 week
were positive stained by the endothelial markers, with the excep-
tion of CD31, although a general reduction in the expression of
the endothelial antigens and the acLDL uptake was observed after
2 weeks (Table 1).
More than 95% of BMMCs committed to the pre-endothelial
cell phenotype under the fibronectin culture condition after just
1 week and maintained the pattern of endothelial markers up to
the third week (Table 1). A similar behavior was observed for
BMMCs exposed to the gelatin medium. Only the uptake of
acLDL decreased after the second week, independently of the me-
dium used; this was probably related to the detachment and re-
plating of confluent BMMCs that can be responsible for partial
damage of the scavenger receptor.
3.1.2. PBMMC and BMMC
Proliferation and Viability
under Endothelial Cell
Differentiating Conditions
The ability of PBMC to expand was very low, irrespective of the
culture medium. In particular, PBMCs cultured on fibronectin-
coated dishes never did reach confluence throughout the study.
Cell confluence was observed only in 30% of dishes under the gel-
Table 1
Antigen pattern of PBMCs and BMMCs cultured under endothelial differentiating
conditions
PBMC/F PBMC/G BMMC/F = BMMC/G
d7 d14 d21 d7 d14 d21 d7 d14 d21
AcLDL 4+ 4+ 4+ 4+ 3+ 2+ 4+ 3+ 1+
BS-I 4+ 4+ 4+ 4+ 3+ 3+ 4+ 4+ 4+
VEGFR-2 3+ 4+ 4+ 4+ 3+ 3+ 4+ 4+ 4+
CD31 1+ 1+ 1+ 1+ 1+ 1+ 1+ 1+ 1+
Macrophage 1+ 1+ 1+ 1+ 1+ 1+ 1+ 1+ 1+
CD90 - - - - - - - - -
Cells were observed by use of an inverted fluorescence microscope after 7, 14, and 21 days under fibro-
nectin (F) or gelatin (G) culture condition. Cell counting was performed by calculating the cell average
number of 10 randomly selected high-power fields (×200) of 3 separate experiments
AcLDL and BS-I were Dil and FITC conjugated, respectively. Immunofluorescence of VEGFR-2,
CD31, macrophage antigen, and CD90 was detected by FITC-conjugated polyclonal secondary antibod-
ies. The pattern of markers evaluated for BMMCs gave the same results irrespective of the culture con-
dition
Fluorescence scores: 4+ 990%, 3+ 50–90%, 2+ 20–50%, 1+ G20%, - no fluorescence
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atin culture condition and, in any case, not before 2 weeks from
cell seeding (Table 2). Post-confluent PBMCs did not keep
proliferating.
Differently from PBMCs, BMMCs showed a high prolifera-
tion rate, especially with the gelatin medium (Table 2). BMMCs
mostly reached confluence in a shorter time with respect to
PBMCs. Moreover, BMMCs became rapidly confluent even after
the second passage.
In contrast, PBMCs grown in the fibronectin medium were
more viable than those cultured in the gelatin medium, as evalu-
ated by the Alamar blue test (Fig. 1, left upper diagrams).
BMMCs treated with the fibronectin medium maintained
their viability constant throughout the experiment, even after cell
replating (Fig. 1, left upper diagrams), whereas BMMCs cultured
on gelatin-coated dishes increased their viability over time, even
after the first passage. The positive effect on BMMC viability ob-
served under the gelatin culture condition was probably enhanced
by the presence of an elevated number of cells which, thanks to
their own paracrine mitogenic function (24), exhibited a high rate
of proliferation (Table 2).
In order to understand which component of the gelatin cul-
ture condition was responsible for cell viability, we differently
combined some characteristics of the two formulations, by grow-
ing BMMCs on fibronectin-coated dishes supplemented with the
EGM-2 solution (Fig. 1, lower diagrams). Under this intermedi-
ate culture condition, the viability of BMMCs rapidly increased
within the first 18 days and showed a further increment up to
the first week after cell re-seeding. Therefore, we suggest that
the improved viability of BMMCs was dependent on the specific
cocktail of growth factors which were present in the gelatin medi-
um rather than gelatin in itself.
Table 2
Comparison between the proliferation potential of treated PBMCs and BMMCs
PBMC/F PBMC/G BMMC/F BMMC/G
% dishes with confluent cells 0 30 60 100
Confluence time 92 wk G2 wk G2 wk
% increase in 1st passage cell-number 0 50 70
% increase in 2nd passage cell-number 20 50
The trypan blue exclusion staining was performed to quantify cells which were grown under fibronectin
(F) or gelatin (G) culture condition. Re-seeding was carried out when cells reached confluence. Cell
counting was performed by calculating the cell average number of 10 randomly selected high-power fields
(×200) of 5 separate experiments. The percentage increase in the post-confluent cell number was calcu-
lated 1 week after re-seeding
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Both proliferation potential and viability were also investi-
gated in those BMMCs which were suspended in the cell me-
dium during the first 3 days of culture. This study was
performed because these cells are sometimes evaluated for
their ability to generate endothelial cells. The behavior of
these cells was similar to that of the early-adherent BMMCs,
although their rate of proliferation and their viability were in-
ferior (n=4, data not shown).
Fig. 1. Time-course of PBMC and BMMC viability exposed to endothelial differentiating conditions.
Cell viability was assessed by the Alamar Blue assay as described in the Methods section. Plots are
representative of 5 separate experiments performed in triplicate. A.U.F. Arbitrary units of fluores-
cence. Upper diagrams. Plots on the left show the time-course of cells seeded just after isolation
and never detached from the culture dish till confluence. Plots on the right show the behavior of cell
re-seeding following the first confluence. Cells were grown under fibronectin (F ) or gelatin (G ) culture
conditions. Lower diagrams. The viability of BMMCs grown under the intermediate culture condition
(I ) is shown before (left ) and after (right ) first-passage re-seeding.
Optimization of Pig Mononuclear Cells for Neovasculogenesis 97
3.1.3. Adhesion
and Viability
of BMMC-Derived EPCs
Cultured on a
Hyaluronan-Based Scaffold
Figure 2 shows the early changes in viability of BMMCs under
fibronectin-, gelatin-, and intermediate culture conditions
grown on HYAFF®11. We previously described the ultrastruc-
tural features of this scaffold and the properties of human
eEPCs cultured onto its fibers (23). The percentage of pig
BMMCs adhesion to the fibers after 24 h from seeding was
more than 95% under all culture conditions. Cell adhesion
was evaluated in post-confluence BMMCs and was higher than
90% (data not shown). A few cells which did not adhere to the
fibers were positive to trypan blue staining and remained sus-
pended in the culture medium, whilst others remained layered
on the bottom of the well.
The viability of BMMCs pre-cultured in the fibronectin me-
dium markedly decreased after 3 days from seeding on the scaf-
fold. In contrast, BMMCs which were pre-treated with gelatin
or intermediate medium significantly increased their viability. This
confirms that EPCs derived from BMMCs show a better metab-
olism when cultured with the EGM-2 solution even when seeded
on a polymer scaffold.
3.1.4. BMMC-Induced
Formation of Tubule-Like
Structures
We performed the standard test on Matrigel to investigate cell
ability to generate vessel-like structures. HUVECs were used ei-
ther as a positive control (alone) or as a cellular network to sustain
the angiogenic activity of the EPCs used in the present work.
BMMCs pre-treated with the fibronectin medium generated
well-defined tubule-like structures (Fig. 3b) which were similar
to those formed by HUVECs alone (Fig. 3a). In addition, the
ability of BMMCs to integrate with the HUVEC network was sat-
isfactory, since cell rings were well surrounded and intercalated by
FITC-BS-I-labelled BMMCs (Fig. 3c,d).
BMMCs exposed to the gelatin culture condition were less
prone to form vessel-like structures. Some of them remained iso-
Fig. 2. Viability of treated BMMCs cultured on HYAFF®11. The viability
of endothelial-committed BMMCs was evaluated by the Alamar Blue as-
say during the first 3 days of cell growth on HYAFF®11. Cell pre-tretment
was performed under fibronectin (F ), gelatin (G ), or intermediate (I ) culture
condition. Bar graphs are representative of 3 separated experiments per-
formed in triplicate. A.U.F. Arbitrary units of fluorescence.
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lated as single cell aggregates, spreading limited cell extensions
along radial directions (Fig. 3e). Moreover, they did not always
originate completely interconnected rings (Fig. 3f) although
FITC-BS-I-labeled BMMCs could intercalate themselves in the
HUVEC network (Fig. 3g, h).
Fig. 3. In vitro tubule-like structure formation driven by pre-treated BMMCs. The micrographs are
representative of 3 separate experiments. HUVECs alone generated well-defined capillary-like struc-
tures on Matrigel (a, ×100. BMMCs pre-treated with the fibronectin medium and seeded on Matrigel
formed a similar network either alone (b, ×100) or with HUVECs (c,d). These co-cultures were ob-
served under phase contrast (c) or fluorescence (d) microscopy to evidence CFDA-labelled BMMCs
(×200). When BMMCs were pre-treated with the gelatin medium, they produced single agglomerates
(e, ×100) or interrupted rings (f, ×100). BMMCs treated with the gelatin medium developed networks
when cultured with HUVECs (g, phase contrast; h, fluorescence of FITC-BS-I-labeled BMMCs).
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3.2. Experiments
with MSCs
3.2.1. MSC Commitment
to the Endothelial Cell
Lineage
We also investigated the commitment to endothelial cells of
MSCs, a naturally occurring stem cell population which resides
in bone marrow and other tissues (25). Table 3 shows that un-
treated MSCs (day 0) were markedly positive for CD90; this find-
ing is in agreement with a previous report (26). In contrast, these
cells were completely negative for the macrophage antigen. The
uptake of acLDL was also not reported in the untreated MSCs,
while BS-I binding and VEGFR-2 antigen expression were ob-
served only in 10% MSCs. After 1-week exposure to the fibronec-
tin medium, 10–20% of MSCs were otherwise able to uptake
acLDL and bind BS-I, while about 50% of MSCs expressed
VEGFR-2. A parallel and complete disappearance of CD90 was
also observed after 1 week. Similar changes were induced in MSCs
under the gelatin culture condition.
3.2.2. MSC-Induced
Formation of Tubule-Like
Structures
Despite the negligible presence of endothelial markers, the
untreated MSCs seeded on Matrigel were able to arrange
some wide-sized rings (Fig. 4a) and to partially contribute
to the HUVEC-driven network (Fig. 4b, c). In this case,
we labeled HUVEC with the fluorescent lectin rather than
MSCs since these latter did not bind it well. The ability to
produce tubule-like structures was improved by using treated
MSCs; in fact, irrespective of the culture condition used they
Table 3
Phenotypic changes of MSCs exposed to endothelial differentiating conditions
Day 0 Day 7 (F = G)
AcLDL - 1+
BS-I 1+ 1+
VEGFR-2 1+ 2+
CD31 1+ 1+
Macrophage - -
CD90 3+ -
MSCs were labelled with the fluorescent dyes described in the legend of Table 1 and observed under fluo-
rescence microscopy. MSCs were grown under standard basal condition (Day 0) and under fibronectin
(F) or gelatin (G) culture condition for 7 days (Day 7). There were no substantial differences between
MSCs cultured with these two different media (F = G)
Cell counting was performed by calculating the cell average number of 10 randomly selected high-pow-
er fields (×200) of 3 separated experiments
Fluorescence score: 3+ 50–90%, 2+ 20–50%, 1+ G20%, - no fluorescence
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originated closed rings (Fig. 4d, g) and better participated in
the HUVEC-mediated capillary formation (Fig. 4e, f, h, i).
4. Discussion
Judging from the positive staining for the endothelial markers, the
combinationof high concentrationofVEGF togetherwith fibronec-
tin substrate produced a reliable EPC phenotype in PBMCs which
was maintained longer than under the gelatin culture condition.
However, the low expression of CD31 indicates that complete mat-
uration could not be achieved during the 3-week exposure to both
differentiating media. Differently from PBMCs, more than 90% of
BMMCs could bind BS-I and express VEGFR-2 up to 3 weeks
under the gelatin culture condition. Thus, BMMCs are more prone
Fig. 4. In vitro tubule-like structure formation by untreated MSCs or MSCs cultured with endothelial
differentiating media. Untreated MSCs were cultured alone (a) or with HUVECs (b,c). MSCs pre-treated
with fibronectin or gelatin medium were also cultured alone (d and g, respectively) or with HUVECs (e,f
and h,i, respectively). FITC-UEA-1-labeled HUVECs co-cultured with MSCs are shown in (c), (f) and (i).
The micrographs are representative of triplicate experiments performed using MSCs on Matrigel.
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than PBMCs to maintain over time an EPC phenotype when
exposed to the gelatin-based differentiating conditions.
Cell proliferation was markedly affected by both the bio-
logical sources of mononuclear cells and the culture conditions.
PBMCs showed a very low attitude to proliferate, although
they reacted better to the gelatin medium. Only under this lat-
ter condition was it possible to obtain PBMC confluence in
30% of culture dishes, but only after 20 days since cell seeding.
However, confluent cells were not able to proliferate any more.
In contrast, more than 60% of BMMCs grown in the fibronec-
tin medium could rapidly expand and reach confluence even at
the second passage within 3 weeks. This finding is in agreement
with the report of Mertsching et al. (27) who expanded pig
BMMCs under the same culture conditions. We obtained the
best proliferation performance with BMMCs exposed to the
gelatin-based formulation, since in 100% dishes it was possible
to re-split cells and increase cell number over 50% after 1 week
from each re-seeding. Although proliferation was better in-
duced by gelatin rather than fibronectin culture condition,
the latter composition allowed PBMCs to be more viable up
to the first confluence. A possible explanation may be the effi-
cacy by which cells adhere to the culture dish, since a high
number of cell contacts stimulate survival pathways in most
cells (anoikis) (28). Fibronectin is known, indeed, to bind cells
through a wide pattern of integrins and other receptor-like
structures, hence affecting endothelial cell viability and func-
tions (29–31). Moreover, VEGF was present in the fibronectin
medium at a high level, thus improving cell survival (32).
In contrast, BMMC viability was positively affected by the
gelatin medium based on their more elevated rate of cell prolifer-
ation. This was especially evident during the second passage when
the exponential growth of BMMCs was more pronounced. To
better understand which was the relative involvement of the cul-
ture components on the behaviour of BMMCs, we studied a third
condition in which cells were grown on fibronectin-coated dishes
in the presence of EGM-2 solution. The viability of BMMCs was
similar to those obtained with the gelatin-based formulation, sug-
gesting that these two processes were stimulated by the higher
amount of IGF-1 and FGF-2, together with EGF, since they syn-
ergistically increase cell growth and survival (33,34). The unat-
tached BMMCs which remained suspended in the medium
during the first 3 days of culture were also able to subsequently
adhere to the coated dishes and expand; thus, we suggest that
the amount of BMMC-derived EPCs can be further increased
by simultaneously growing both early-suspended and adherent
cells under the same culture conditions.
As a consequence of these preliminary results, we decided not
to perform further investigations on PBMCs-derived EPCs be-
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cause they showed a poor proliferative potential. We did not try to
mobilize EPCs from bone marrow, i.e. by means of the granulo-
cyte colony-stimulating factor (G-CSF), because the yield of these
cells in peripheral blood is, in any case, lower than that registered
by using bone marrow itself (13,35).
Among the natural polymers which are commonly used as
suitable scaffolds for regenerative medicine, the hyaluronan-based
materials show interesting features because they are biocompati-
ble, biodegradable, and can stimulate biological activities through
hyaluronan-related cell receptors (36). Several approaches of cell
therapy need rapid vascularization during the regeneration of
the damaged tissue; in this case, hyaluronan plays a beneficial
role not only as a cell vehicle but also because it can activate
neoangiogenesis through the slow release of its naturally de-
graded fragments (37).
The percentage of the BMMC-derived EPCs which adhered
to the scaffold was higher than 90%, irrespective of the differenti-
ating medium, and even using second-passage cells. This latter
finding suggests that we can expand post-confluent cells and also
obtain an almost complete adhesion of these EPCs to the scaffold.
In a previous report, we suggested the transplanting in vivo of
HYAFF®11 engineered with human EPCs after just a few days
from cell seeding in order to obtain the best effects on neovascu-
larization (23); therefore, we investigated the viability of treated
BMMCs within 3 days of culture on the scaffold. As for cultures
on coated dishes, the best viability was observed by pre-treating
BMMCs under gelatin or intermediate culture condition. Also un-
der these conditions, BMMC growth on a hyaluronan-base poly-
mer was attributable to the positive effects elicited by IGF-1,
FGF-2, and EGF.
The ability of BMMCs to generate a tubule-like network was
evaluated using Matrigel as a standard substrate. The pre-treatment
of BMMCs with the fibronectin medium allowed the formation of
three-dimensional rings which were without gaps, like those derived
from HUVECs. Under this condition, BMMCs were also able to
plug into theHUVEC network, extending thin connections formed
by single cell layers such as during the in vivo capillary formation.
Therefore, BMMCs treated with the fibronectin medium showed
both angiogenic- and vasculogenic-like properties in vitro. In con-
trast, the gelatin medium was not as efficient as the fibronectin
one to prime BMMCs alone for tubule-like formation.
Taken together, these results suggest that a leading protocol to
obtain a suitable number of specialized EPCs for neovascularization
could be to expand BMMCs with the gelatin-based formulation
and to expose them to the fibronectin medium to optimize their
ability to produce a reliable capillary network. An alternative strat-
egy was the one adopted by Serrano et al. (38), which was charac-
terized by exposing pig PMBCs to EGM-2 for 2 weeks and then
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depriving the medium of FGF-2 with the purpose of enhancing en-
dothelial differentiation in this second phase of culture.
The study of both function and differentiation of MSCs gave
further useful information. First of all, MSCs alone and in the ab-
sence of any pre-treatment with endothelial differentiating media
could form initial and rough tubule-like structures in Matrigel. As
a matter of fact, the test we used to evaluate tubule-like formation
on Matrigel is not exclusive for capillary structures, but allows the
circular joining of other kinds of cells, such as fibroblasts (39).
Since native MSCs did not show a pattern of endothelial markers,
it is likely that their attempt to create a cell network was mainly
referred to their mesenchymal phenotype. MSCs, together with
EPCs, indeed represent an excellent mixed cell population that
has been described as originating capillaries with pericytes (14)
and vessels of middle/large size provided with a complete vascular
wall (40).
One main limitation of the present work is the lack of investiga-
tion about pig EPCs obtained by selecting an antigen expressed by
very early immature precursor cells, i.e. CD34 and CD133, or by
the expansion of endothelial cell-forming colony units. However,
both these protocols yield fewEPCs in a short time, thereby reducing
their availability for precocious intervention of cardiac regeneration.
Nevertheless, these cells can also be greatly expanded, but the time
available to obtain a suitable number of functional EPCs for clinical
applications is about 2 months. Another limit of this research is the
absence of studies related to EPC migration and EPC release of an-
giogenic factors. The assay of in vitro tubule-like structure formation
that was performed in the present work should also include these
EPC activities, although caution is needed to directly correlate this
morphological assay with endothelial functionality in vivo (41).
In conclusion, pig BMMCs are preferentially expanded rather
than differentiated to endothelial cells using high concentrations
of IGF-1 and FGF-2, in the presence of EGF and a low level of
VEGF. In contrast, fibronectin-coated dishes supplemented
with an elevated amount of VEGF and lower concentrations
of IGF-1 and FGF-2 can be considered a good formulation
to produce capillary-like structures by BMMCs. Therefore,
these two different protocols could be followed and integrated
to prepare a large number of specialized EPCs as a useful
strategy to modulate neovascularization.
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